{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:12:42Z","timestamp":1790712762385,"version":"4.1.0"},"reference-count":191,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CIMB"],"abstract":"<jats:p>Myeloproliferative neoplasms are clonal hematological neoplasms characterized by excessive proliferation of cells of erythroid, granulocytic, and megakaryocytic lineage. The genetic mechanisms underlying this group of blood diseases are now known, but new perspectives have recently emerged in the field of epigenetics and particularly related to the possible role of DNA methylation in disease development and progression. DNA methylation regulates different cellular processes, such as proliferation, differentiation, and apoptosis. In myeloproliferative neoplasms, a link has been found between abnormal methylation patterns, such as hypermethylation of tumor suppressors or, conversely, oncogenes hypomethylation, with the progression of the disease, spreading important prognostic and therapeutic implications. This review aims to investigate the relationship between methylation alterations and myeloproliferative neoplasms, emphasizing the ways by which epigenetic dysregulation promotes disease biology.<\/jats:p>","DOI":"10.3390\/cimb47040227","type":"journal-article","created":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T03:35:28Z","timestamp":1743132928000},"page":"227","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["DNA Methylation in Ph-Negative Myeloproliferative Neoplasms: Prognostic Role and Therapeutic Implications"],"prefix":"10.3390","volume":"47","author":[{"given":"Paola","family":"Barone","sequence":"first","affiliation":[{"name":"Hematology Unit, Department of Human Pathology in Adulthood and Childhood \u201cGaetano Barresi\u201d, University of Messina, Via Consolare Valeria, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adele","family":"Bottaro","sequence":"additional","affiliation":[{"name":"Hematology Unit, Department of Human Pathology in Adulthood and Childhood \u201cGaetano Barresi\u201d, University of Messina, Via Consolare Valeria, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossana","family":"Leanza","sequence":"additional","affiliation":[{"name":"Hematology Unit, Department of Human Pathology in Adulthood and Childhood \u201cGaetano Barresi\u201d, University of Messina, Via Consolare Valeria, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7947-158X","authenticated-orcid":false,"given":"Fabio","family":"Stagno","sequence":"additional","affiliation":[{"name":"Hematology Unit, Department of Human Pathology in Adulthood and Childhood \u201cGaetano Barresi\u201d, University of Messina, Via Consolare Valeria, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Allegra","sequence":"additional","affiliation":[{"name":"Hematology Unit, Department of Human Pathology in Adulthood and Childhood \u201cGaetano Barresi\u201d, University of Messina, Via Consolare Valeria, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Roszkowska, A.M., Leanza, R., Aragona, E., Gargiulo, L., Alibrandi, A., Arrigo, A., Bottaro, A., Barone, P., Stagno, F., and Allegra, A. (2024). Retinal Vessel Analysis and Microvascular Abnormalities in Patients with Philadelphia-Negative Chronic Myeloproliferative Neoplasms. J. Clin. Med., 13.","DOI":"10.3390\/jcm13082232"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.molmed.2005.10.003","article-title":"A JAK2 mutation in myeloproliferative disorders: Pathogenesis and therapeutic and scientific prospects","volume":"11","author":"James","year":"2005","journal-title":"Trends Mol. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.exphem.2015.06.007","article-title":"Pathogenesis of myeloproliferative neoplasms","volume":"43","author":"Skoda","year":"2015","journal-title":"Exp. Hematol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1056\/NEJMoa1716614","article-title":"Classification and Personalized Prognosis in Myeloproliferative Neoplasms","volume":"379","author":"Grinfeld","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3904\/kjim.2019.317","article-title":"Recent insights regarding the molecular basis of myeloproliferative neoplasms","volume":"35","author":"Jang","year":"2020","journal-title":"Korean J. Intern. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1080\/09537100600758677","article-title":"Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: A distinct aspirin-responsive and coumadin-resistant arterial thrombophilia","volume":"17","author":"Michiels","year":"2006","journal-title":"Platelets"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/bs.ircmb.2021.09.002","article-title":"The JAK2 mutation","volume":"365","author":"Merchant","year":"2021","journal-title":"Int. Rev. Cell Mol. Biol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.hoc.2020.12.001","article-title":"Overview of Myeloproliferative Neoplasms: History, Pathogenesis, Diagnostic Criteria, and Complications","volume":"35","author":"Tremblay","year":"2021","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa065202","article-title":"JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis","volume":"356","author":"Scott","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1182\/blood.2022017697","article-title":"JAK2 V617F allele burden in polycythemia vera: Burden of proof","volume":"141","author":"Moliterno","year":"2023","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e333","DOI":"10.1097\/HS9.0000000000000333","article-title":"Mutant Calreticulin in the Myeloproliferative Neoplasms","volume":"4","author":"Prins","year":"2020","journal-title":"Hemasphere"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"Nangalia","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1182\/blood.2024024714","article-title":"Essential thrombocythemia with MPL W515S mutation","volume":"144","author":"Thorburn","year":"2024","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"12367","DOI":"10.2147\/OTT.S287944","article-title":"Impact of Mutational Profile on the Management of Myeloproliferative Neoplasms: A Short Review of the Emerging Data","volume":"13","author":"Loscocco","year":"2020","journal-title":"Onco Targets Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/s41375-019-0564-z","article-title":"Mutant calreticulin interacts with MPL in the secretion pathway for activation on the cell surface","volume":"34","author":"Masubuchi","year":"2020","journal-title":"Leukemia"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1182\/asheducation-2018.1.110","article-title":"JAK2 (and other genes) be nimble with MPN diagnosis, prognosis, and therapy","volume":"2018","author":"Ciboddo","year":"2018","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Grabek, J., Straube, J., Bywater, M., and Lane, S.W. (2020). MPN: The Molecular Drivers of Disease Initiation, Progression and Transformation and their Effect on Treatment. Cells, 9.","DOI":"10.3390\/cells9081901"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1038\/leu.2009.141","article-title":"Mutations of ASXL1 gene in myeloproliferative neoplasms","volume":"23","author":"Carbuccia","year":"2009","journal-title":"Leukemia"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1182\/asheducation-2013.1.538","article-title":"Focus on the epigenome in the myeloproliferative neoplasms","volume":"2013","author":"Kim","year":"2013","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/npp.2012.112","article-title":"DNA methylation and its basic function","volume":"38","author":"Moore","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1101\/gr.270066.120","article-title":"Hydroxycarbamide effects on DNA methylation and gene expression in myeloproliferative neoplasms","volume":"31","author":"Montibus","year":"2021","journal-title":"Genome Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/cr.2011.22","article-title":"Regulation of chromatin by histone modifications","volume":"21","author":"Bannister","year":"2011","journal-title":"Cell Res."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Audia, J.E., and Campbell, R.M. (2016). Histone Modifications and Cancer. Cold Spring Harb. Perspect. Biol., 8.","DOI":"10.1101\/cshperspect.a019521"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Allegra, A., Caserta, S., Mirabile, G., and Gangemi, S. (2023). Aging and Age-Related Epigenetic Drift in the Pathogenesis of Leukemia and Lymphomas: New Therapeutic Targets. Cells, 12.","DOI":"10.3390\/cells12192392"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"5818","DOI":"10.1158\/0008-5472.CAN-05-0197","article-title":"Phosphorylation of histone H3 at serine 10 is indispensable for neoplastic cell transformation","volume":"65","author":"Choi","year":"2005","journal-title":"Cancer Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/nsmb.2518","article-title":"DNA methylation dynamics in health and disease","volume":"20","author":"Bergman","year":"2013","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s13238-021-00846-7","article-title":"Metabolic reprogramming and epigenetic modifications on the path to cancer","volume":"13","author":"Sun","year":"2022","journal-title":"Protein Cell"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Greenfield, G., and McMullin, M.F. (2023). Epigenetics in myeloproliferative neoplasms. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1206965"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"6305","DOI":"10.1158\/0008-5472.CAN-04-2957","article-title":"Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases","volume":"65","author":"Brueckner","year":"2005","journal-title":"Cancer Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1186\/s12935-023-03074-7","article-title":"Methylomics and cancer: The current state of methylation profiling and marker development for clinical care","volume":"23","author":"Liu","year":"2023","journal-title":"Cancer Cell Int."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1158\/1078-0432.CCR-16-1371","article-title":"Early Detection of Lung Cancer Using DNA Promoter Hypermethylation in Plasma and Sputum","volume":"23","author":"Hulbert","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"6101","DOI":"10.1158\/0008-5472.CAN-19-1019","article-title":"Histone-Related Genes Are Hypermethylated in Lung Cancer and Hypermethylated HIST1H4F Could Serve as a Pan-Cancer Biomarker","volume":"79","author":"Dong","year":"2019","journal-title":"Cancer Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa0810069","article-title":"Mutation in TET2 in myeloid cancers","volume":"360","author":"Delhommeau","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1038\/ng.391","article-title":"Acquired mutations in TET2 are common in myelodysplastic syndromes","volume":"41","author":"Langemeijer","year":"2009","journal-title":"Nat. Genet."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/bjc.2016.36","article-title":"Inhibition of histone deacetylases in cancer therapy: Lessons from leukaemia","volume":"114","author":"Ceccacci","year":"2016","journal-title":"Br. J. Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1042\/bj20021321","article-title":"Histone deacetylases (HDACs): Characterization of the classical HDAC family","volume":"370","author":"Caron","year":"2003","journal-title":"Biochem. J."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.15252\/embr.201541113","article-title":"Histone demethylases in chromatin biology and beyond","volume":"16","author":"Dimitrova","year":"2015","journal-title":"EMBO Rep."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Eckschlager, T., Plch, J., Stiborova, M., and Hrabeta, J. (2017). Histone Deacetylase Inhibitors as Anticancer Drugs. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18071414"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd4360","article-title":"Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders","volume":"13","author":"Falkenberg","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1053\/j.seminhematol.2020.12.005","article-title":"Epigenetic modifiers in normal and aberrent erythropoeisis","volume":"58","author":"Sundaravel","year":"2021","journal-title":"Semin. Hematol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/nrc3343","article-title":"The role of mutations in epigenetic regulators in myeloid malignancies","volume":"12","author":"Shih","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"7344","DOI":"10.1038\/s41467-022-35059-x","article-title":"EZH2-H3K27me3 mediated KRT14 upregulation promotes TNBC peritoneal metastasis","volume":"13","author":"Verma","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"a034876","DOI":"10.1101\/cshperspect.a034876","article-title":"The Molecular Genetics of Myeloproliferative Neoplasms","volume":"10","author":"Marneth","year":"2020","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrc2210","article-title":"Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders","volume":"7","author":"Levine","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/j.exphem.2007.09.008","article-title":"Epigenetic control of PRV-1 expression on neutrophils","volume":"35","author":"Jelinek","year":"2007","journal-title":"Exp. Hematol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/S0301-472X(02)00883-4","article-title":"Current understanding of stem cell mobilization: The roles of chemokines, proteolytic enzymes, adhesion molecules, cytokines, and stromal cells","volume":"30","author":"Lapidot","year":"2002","journal-title":"Exp. Hematol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/ni813","article-title":"G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4","volume":"3","author":"Petit","year":"2002","journal-title":"Nat. Immunol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S1074-7613(00)80046-1","article-title":"The chemokine receptor CXCR4 is required for the retention of B lineage and granulocytic precursors within the bone marrow microenvironment","volume":"10","author":"Ma","year":"1999","journal-title":"Immunity"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"4307","DOI":"10.1182\/blood.V99.12.4307","article-title":"Enhancement of intracellular signaling associated with hematopoietic progenitor cell survival in response to SDF-1\/CXCL12 in synergy with other cytokines","volume":"99","author":"Lee","year":"2002","journal-title":"Blood"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1084\/jem.185.1.111","article-title":"The chemokine SDF-1 is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood","volume":"185","author":"Aiuti","year":"1997","journal-title":"J. Exp. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"4508","DOI":"10.1182\/blood-2004-08-3238","article-title":"Constitutive mobilization of CD34+ cells into the peripheral blood in idiopathic myelofibrosis may be due to the action of a number of proteases","volume":"105","author":"Xu","year":"2005","journal-title":"Blood"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1172\/JCI7615","article-title":"The chemokine SDF-1 stimulates integrin-mediated arrest of CD34(+) cells on vascular endothelium under shear flow","volume":"104","author":"Peled","year":"1999","journal-title":"J. Clin. Investig."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"6417","DOI":"10.1158\/0008-5472.CAN-07-0572","article-title":"Effects of chromatin-modifying agents on CD34+ cells from patients with idiopathic myelofibrosis","volume":"67","author":"Shi","year":"2007","journal-title":"Cancer Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1634\/stemcells.2008-0377","article-title":"Hypermethylation of CXCR4 promoter in CD34+ cells from patients with primary myelofibrosis","volume":"26","author":"Bogani","year":"2008","journal-title":"Stem Cells"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s11899-011-0105-y","article-title":"Disordered epigenetic regulation in the pathophysiology of myeloproliferative neoplasms","volume":"7","author":"Zhang","year":"2012","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/sj.leu.2404513","article-title":"Epigenetic alterations complement mutation of JAK2 tyrosine kinase in patients with BCR\/ABL-negative myeloproliferative disorders","volume":"21","author":"Jost","year":"2007","journal-title":"Leukemia"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.3324\/haematol.2013.084160","article-title":"Aberrant DNA methylation profile of chronic and transformed classic Philadelphia-negative myeloproliferative neoplasms","volume":"98","author":"Pascual","year":"2013","journal-title":"Haematologica"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/nature09586","article-title":"Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2","volume":"468","author":"Ko","year":"2010","journal-title":"Nature"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1038\/leu.2010.20","article-title":"Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia","volume":"24","author":"Boultwood","year":"2010","journal-title":"Leukemia"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"127","DOI":"10.4161\/epi.1.3.3327","article-title":"Functional analysis of promoter CpG methylation using a CpG-free luciferase reporter vector","volume":"1","author":"Klug","year":"2006","journal-title":"Epigenetics"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1101\/gr.118703.110","article-title":"Cell type-specific DNA methylation at intragenic CpG islands in the immune system","volume":"21","author":"Deaton","year":"2011","journal-title":"Genome Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1091\/mbc.e10-01-0040","article-title":"ZFP36L1 negatively regulates erythroid differentiation of CD34+ hematopoietic stem cells by interfering with the Stat5b pathway","volume":"21","author":"Vignudelli","year":"2010","journal-title":"Mol. Biol. Cell"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.leukres.2018.02.017","article-title":"ZFP36L2, a novel AML1 target gene, induces AML cells apoptosis and inhibits cell proliferation","volume":"68","author":"Liu","year":"2018","journal-title":"Leuk. Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1182\/blood.V108.11.118.118","article-title":"Hypermethylation of SH2-Containing Phosphatase-1 (SHP-1) and Suppressor of Cytokine Signaling-1 and -3 (SOCS-1 and -3) in Philadelphia Negative Chronic Myeloproliferative Disorders","volume":"108","author":"Rossi","year":"2008","journal-title":"Blood"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"3374","DOI":"10.1182\/blood-2005-05-1889","article-title":"Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2","volume":"106","author":"Kralovics","year":"2005","journal-title":"Blood"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1126\/science.aad5978","article-title":"RNA-binding proteins ZFP36L1 and ZFP36L2 promote cell quiescence","volume":"352","author":"Galloway","year":"2016","journal-title":"Science"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1080\/10428190601043138","article-title":"Overexpression of SOCS-2 and SOCS-3 genes reverses erythroid overgrowth and IGF-I hypersensitivity of primary polycythemia vera (PV) cells","volume":"48","author":"Usenko","year":"2007","journal-title":"Leuk. Lymphoma"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1182\/blood-2007-01-069237","article-title":"Different STAT-3 and STAT-5 phosphorylation discriminates among Ph-negative chronic myeloproliferative diseases and is independent of the V617F JAK-2 mutation","volume":"110","author":"Teofili","year":"2007","journal-title":"Blood"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"14133","DOI":"10.1073\/pnas.2232790100","article-title":"SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer","volume":"100","author":"He","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/ng0501-29","article-title":"SOCS-1, a negative regulator of the JAK\/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity","volume":"28","author":"Yoshikawa","year":"2001","journal-title":"Nat. Genet."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/nri2093","article-title":"SOCS proteins, cytokine signalling and immune regulation","volume":"7","author":"Yoshimura","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1365-2141.2006.06293.x","article-title":"Clinical implications of SOCS1 methylation in myelodysplastic syndrome","volume":"135","author":"Wu","year":"2006","journal-title":"Br. J. Haematol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1136\/gut.2006.111633","article-title":"Methylation of SOCS-3 and SOCS-1 in the carcinogenesis of Barrett\u2019s adenocarcinoma","volume":"56","author":"Tischoff","year":"2007","journal-title":"Gut"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1158\/0008-5472.CAN-12-0735","article-title":"Methylome profiling reveals distinct alterations in phenotypic and mutational subgroups of myeloproliferative neoplasms","volume":"73","author":"Nischal","year":"2013","journal-title":"Cancer Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.3324\/haematol.2018.204917","article-title":"Epigenomic profiling of myelofibrosis reveals widespread DNA methylation changes in enhancer elements and ZFP36L1 as a potential tumor suppressor gene that is epigenetically regulated","volume":"104","author":"Pascual","year":"2019","journal-title":"Haematologica"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1002\/ijc.23694","article-title":"Epigenetic alteration of SOCS family members is a possible pathogenetic mechanism in JAK2 wild type myeloproliferative diseases","volume":"123","author":"Teofili","year":"2008","journal-title":"Int. J. Cancer"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/j.exphem.2007.08.021","article-title":"Regulated expression of microRNAs in normal and polycythemia vera erythropoiesis","volume":"35","author":"Bruchova","year":"2007","journal-title":"Exp. Hematol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/hon.694","article-title":"Hypermethylation of gene promoters in hematological neoplasia","volume":"20","author":"Chim","year":"2002","journal-title":"Hematol. Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1158\/0008-5472.CAN-06-4218","article-title":"Genetic unmasking of an epigenetically silenced microRNA in human cancer cells","volume":"67","author":"Lujambio","year":"2007","journal-title":"Cancer Res."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Wong, K.Y., So, C.C., Loong, F., Chung, L.P., Lam, W.W., Liang, R., Li, G.K., Jin, D.Y., and Chim, C.S. (2011). Epigenetic inactivation of the miR-124-1 in haematological malignancies. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0019027"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1111\/j.1582-4934.2011.01274.x","article-title":"Epigenetic inactivation of the hsa-miR-203 in haematological malignancies","volume":"15","author":"Chim","year":"2011","journal-title":"J. Cell. Mol. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/1479-5876-9-197","article-title":"Methylation of miR-34a, miR-34b\/c, miR-124-1 and miR-203 in Ph-negative myeloproliferative neoplasms","volume":"9","author":"Chim","year":"2011","journal-title":"J. Transl. Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1182\/bloodadvances.2018021469","article-title":"The mutational landscape of accelerated- and blast-phase myeloproliferative neoplasms impacts patient outcomes","volume":"2","author":"McNamara","year":"2018","journal-title":"Blood Adv."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/nature07672","article-title":"Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals","volume":"458","author":"Guttman","year":"2009","journal-title":"Nature"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1007\/s00335-015-9583-x","article-title":"Creating reference gene annotation for the mouse C57BL6\/J genome assembly","volume":"26","author":"Mudge","year":"2015","journal-title":"Mamm. Genome"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1126\/science.1231776","article-title":"Epigenetic regulation by long noncoding RNAs","volume":"338","author":"Lee","year":"2012","journal-title":"Science"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1101\/gr.225128.117","article-title":"Cancer-associated rs6983267 SNP and its accompanying long noncoding RNA CCAT2 induce myeloid malignancies via unique SNP-specific RNA mutations","volume":"28","author":"Shah","year":"2018","journal-title":"Genome Res."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/ni.2257","article-title":"Inflammasomes: Far beyond inflammation","volume":"13","author":"Elinav","year":"2012","journal-title":"Nat. Immunol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"956","DOI":"10.4049\/jimmunol.1502060","article-title":"Reassessing the Evolutionary Importance of Inflammasomes","volume":"196","author":"Maltez","year":"2016","journal-title":"J. Immunol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"284706","DOI":"10.1155\/2015\/284706","article-title":"Impact of Inflammation on Myeloproliferative Neoplasm Symptom Development","volume":"2015","author":"Geyer","year":"2015","journal-title":"Mediat. Inflamm."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"101248","DOI":"10.1016\/j.eclinm.2021.101248","article-title":"Patients with MPNs and retinal drusen show signs of complement system dysregulation and a high degree of chronic low-grade inflammation","volume":"43","author":"Liisborg","year":"2021","journal-title":"eClinicalMedicine"},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Karan, D. (2018). Inflammasomes: Emerging Central Players in Cancer Immunology and Immunotherapy. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.03028"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/nature07205","article-title":"Cancer-related inflammation","volume":"454","author":"Mantovani","year":"2008","journal-title":"Nature"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/s41568-019-0123-y","article-title":"Diverging inflammasome signals in tumorigenesis and potential targeting","volume":"19","author":"Karki","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1182\/blood.V124.21.3220.3220","article-title":"Crucial Factors of the Inflammatory Microenvironment Promote Maintenance of the Malignant Hemopoietic Clone of Myelofibrosis by Stimulating Survival and Inhibiting Proliferation of CD34+ stem\/Progenitor Cells","volume":"124","author":"Catani","year":"2014","journal-title":"Blood"},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Allegra, A., Casciaro, M., Barone, P., Musolino, C., and Gangemi, S. (2022). Epigenetic Crosstalk between Malignant Plasma Cells and the Tumour Microenvironment in Multiple Myeloma. Cancers, 14.","DOI":"10.3390\/cancers14112597"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1161\/CIRCRESAHA.118.313283","article-title":"Macrophage Inflammation, Erythrophagocytosis, and Accelerated Atherosclerosis in Jak2 V617F Mice","volume":"123","author":"Wang","year":"2018","journal-title":"Circ. Res."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"102476","DOI":"10.1155\/2015\/102476","article-title":"MPNs as Inflammatory Diseases: The Evidence, Consequences, and Perspectives","volume":"2015","author":"Hasselbalch","year":"2015","journal-title":"Mediat. Inflamm."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jaut.2017.06.010","article-title":"Inflammation and myeloproliferative neoplasms","volume":"85","author":"Lussana","year":"2017","journal-title":"J. Autoimmun."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"43974","DOI":"10.18632\/oncotarget.9949","article-title":"Crucial factors of the inflammatory microenvironment (IL-1\u03b2\/TNF-\u03b1\/TIMP-1) promote the maintenance of the malignant hemopoietic clone of myelofibrosis: An in vitro study","volume":"7","author":"Sollazzo","year":"2016","journal-title":"Oncotarget"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.3324\/haematol.2021.280320","article-title":"ASXL1 mutations accelerate bone marrow fibrosis via EGR1-TNFA axis-mediated neoplastic fibrocyte generation in myeloproliferative neoplasms","volume":"108","author":"Shi","year":"2023","journal-title":"Haematologica"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1038\/leu.2010.69","article-title":"Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1","volume":"24","author":"Tefferi","year":"2010","journal-title":"Leukemia"},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Longhitano, L., Li Volti, G., Giallongo, C., Spampinato, M., Barbagallo, I., Di Rosa, M., Romano, A., Avola, R., Tibullo, D., and Palumbo, G.A. (2020). The Role of Inflammation and Inflammasome in Myeloproliferative Disease. J. Clin. Med., 9.","DOI":"10.3390\/jcm9082334"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1365-2141.2005.05674.x","article-title":"Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases","volume":"130","author":"Panteli","year":"2005","journal-title":"Br. J. Haematol."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Hermouet, S. (2023). Mutations, inflammation and phenotype of myeloproliferative neoplasms. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1196817"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.leukres.2012.10.020","article-title":"Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development?","volume":"37","author":"Hasselbalch","year":"2013","journal-title":"Leuk. Res."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1111\/j.1582-4934.2009.00827.x","article-title":"Epigenetic therapy in myeloproliferative neoplasms: Evidence and perspectives","volume":"13","author":"Vannucchi","year":"2009","journal-title":"J. Cell. Mol. Med."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0950-3536(97)80051-0","article-title":"Megakaryocytes and platelets in myeloproliferative disorders","volume":"10","author":"Briere","year":"1997","journal-title":"Baillieres Clin. Haematol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.1182\/blood.V98.12.3261","article-title":"Ineffective erythropoiesis in Stat5a(-\/-)5b(-\/) mice due to decreased survival of early erythroblasts","volume":"98","author":"Socolovsky","year":"2001","journal-title":"Blood"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"25158","DOI":"10.1074\/jbc.M212849200","article-title":"BCL-2 and BCL-XL restrict lineage choice during hematopoietic differentiation","volume":"278","author":"Haughn","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s10555-007-9080-0","article-title":"The role of the hypoxia-inducible BH3-only proteins BNIP3 and BNIP3L in cancer","volume":"26","author":"Mellor","year":"2007","journal-title":"Cancer Metastasis Rev."},{"key":"ref_113","first-page":"1199","article-title":"Early down-regulation of Bcl-xL expression during megakaryocytic differentiation of thrombopoietin-induced CD34+ bone marrow cells in essential thrombocythemia","volume":"89","author":"Zhang","year":"2004","journal-title":"Haematologica"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s00277-007-0252-3","article-title":"Different involvement of the megakaryocytic lineage by the JAK2 V617F mutation in Polycythemia vera, essential thrombocythemia and chronic idiopathic myelofibrosis","volume":"86","author":"Hussein","year":"2007","journal-title":"Ann. Hematol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1136\/jclinpath-2015-203177","article-title":"Megakaryocytic hyperplasia in myeloproliferative neoplasms is driven by disordered proliferative, apoptotic and epigenetic mechanisms","volume":"69","author":"Malherbe","year":"2016","journal-title":"J. Clin. Pathol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/j.exphem.2008.07.011","article-title":"Expression profiling of apoptosis-related genes in megakaryocytes: BNIP3 is downregulated in primary myelofibrosis","volume":"36","author":"Theophile","year":"2008","journal-title":"Exp. Hematol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1182\/blood-2005-10-009514","article-title":"Constitutive activation of STAT5 and Bcl-xL overexpression can induce endogenous erythroid colony formation in human primary cells","volume":"108","author":"Rivat","year":"2006","journal-title":"Blood"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1073\/pnas.89.5.1827","article-title":"A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands","volume":"89","author":"Frommer","year":"1992","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1093\/bioinformatics\/btx040","article-title":"Genome-wide analysis of DNA methylation profiles in a senescence-accelerated mouse prone 8 brain using whole-genome bisulfite sequencing","volume":"33","author":"Zhang","year":"2017","journal-title":"Bioinformatics"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"e498","DOI":"10.1002\/ctm2.498","article-title":"An epigenomic landscape of cervical intraepithelial neoplasia and cervical cancer using single-base resolution methylome and hydroxymethylome","volume":"11","author":"Han","year":"2021","journal-title":"Clin. Transl. Med."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"2103056","DOI":"10.1183\/13993003.03056-2021","article-title":"Universal lung epithelium DNA methylation markers for detection of lung damage in liquid biopsies","volume":"60","author":"Magenheim","year":"2022","journal-title":"Eur. Respir. J."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"e36","DOI":"10.1093\/nar\/gkw1110","article-title":"Splinted ligation adapter tagging (SPLAT), a novel library preparation method for whole genome bisulphite sequencing","volume":"45","author":"Raine","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Wu, W., Hu, Q., Nie, E., Yu, T., Wu, Y., Zhi, T., Jiang, K., Shen, F., Wang, Y., and Zhang, J. (2017). Hypoxia induces H19 expression through direct and indirect Hif-1\u03b1 activity, promoting oncogenic effects in glioblastoma. Sci. Rep., 7.","DOI":"10.1038\/srep45029"},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Yu, J., Chai, P., Xie, M., Ge, S., Ruan, J., Fan, X., and Jia, R. (2021). Histone lactylation drives oncogenesis by facilitating m6A reader protein YTHDF2 expression in ocular melanoma. Genome Biol., 22.","DOI":"10.1186\/s13059-021-02308-z"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1038\/s41467-018-03590-5","article-title":"C\/EBP\u03b2 enhances platinum resistance of ovarian cancer cells by reprogramming H3K79 methylation","volume":"9","author":"Liu","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ymeth.2020.06.022","article-title":"Modern epigenetics methods in biological research","volume":"187","author":"Li","year":"2021","journal-title":"Methods"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1101\/gr.180240.114","article-title":"Whole-epigenome analysis in multiple myeloma reveals DNA hypermethylation of B cell-specific enhancers","volume":"25","author":"Agirre","year":"2015","journal-title":"Genome Res."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"D183","DOI":"10.1093\/nar\/gkw1138","article-title":"PANTHER version 11: Expanded annotation data from Gene Ontology and Reactome pathways, and data analysis tool enhancements","volume":"45","author":"Mi","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1600-0609.2011.01618.x","article-title":"Whole-blood transcriptional profiling of interferon-inducible genes identifies highly upregulated IFI27 in primary myelofibrosis","volume":"87","author":"Skov","year":"2011","journal-title":"Eur. J. Haematol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1101\/gr.5273806","article-title":"Comparative isoschizomer profiling of cytosine methylation: The HELP assay","volume":"16","author":"Khulan","year":"2006","journal-title":"Genome Res."},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Figueroa, M.E., Reimers, M., Thompson, R.F., Ye, K., Li, Y., Selzer, R.R., Fridriksson, J., Paietta, E., Wiernik, P., and Green, R.D. (2008). An integrative genomic and epigenomic approach for the study of transcriptional regulation. PLoS ONE, 3.","DOI":"10.1371\/journal.pone.0001882"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/75556","article-title":"Gene ontology: Tool for the unification of biology. The Gene Ontology Consortium","volume":"25","author":"Ashburner","year":"2000","journal-title":"Nat. Genet."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1089\/104454904323145245","article-title":"High-throughput gateway bicistronic retroviral vectors for stable expression in mammalian cells: Exploring the biologic effects of STAT5 overexpression","volume":"23","author":"Royer","year":"2004","journal-title":"DNA Cell Biol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"14066","DOI":"10.1073\/pnas.95.24.14066","article-title":"DNA end-joining catalyzed by human cell-free extracts","volume":"95","author":"Baumann","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1182\/blood-2008-01-134114","article-title":"JAK2 stimulates homologous recombination and genetic instability: Potential implication in the heterogeneity of myeloproliferative disorders","volume":"112","author":"Plo","year":"2008","journal-title":"Blood"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"456","DOI":"10.3181\/00379727-119-30209","article-title":"Activity of congeners of hydroxyurea against advanced leukemia L210","volume":"119","author":"Adamson","year":"1965","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1172\/JCI111464","article-title":"Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia","volume":"74","author":"Platt","year":"1984","journal-title":"J. Clin. Investig."},{"key":"ref_139","first-page":"5829","article-title":"Drug-induced DNA hypermethylation and drug resistance in human tumors","volume":"49","author":"Nyce","year":"1989","journal-title":"Cancer Res."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/em.22101","article-title":"The development and validation of EpiComet-Chip, a modified high-throughput comet assay for the assessment of DNA methylation status","volume":"58","author":"Townsend","year":"2017","journal-title":"Environ. Mol. Mutagen."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1182\/blood.V116.21.2670.2670","article-title":"Hydroxyurea induces genome-wide epigenetic changes in sickle cell disease","volume":"116","author":"Garrett","year":"2010","journal-title":"Blood"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/ejh.14247","article-title":"Reviewing the impact of hydroxyurea on DNA methylation and its potential clinical implications in sickle cell disease","volume":"113","author":"Lewis","year":"2024","journal-title":"Eur. J. Haematol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1586\/era.11.10","article-title":"Hydroxycarbamide: A user\u2019s guide for chronic myeloproliferative disorders","volume":"11","author":"Spivak","year":"2011","journal-title":"Expert. Rev. Anticancer Ther."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1080\/10428190290026358","article-title":"Gene expression profiling in chronic myeloid leukemia patients treated with hydroxyurea","volume":"43","author":"Bruchova","year":"2002","journal-title":"Leuk. Lymphoma"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1126\/science.146.3648.1172","article-title":"Hydroxyurea: Inhibitory effect on DNA metabolism","volume":"146","author":"Young","year":"1964","journal-title":"Science"},{"key":"ref_146","doi-asserted-by":"crossref","unstructured":"Chatterjee, A., Stockwell, P.A., Rodger, E.J., Duncan, E.J., Parry, M.F., Weeks, R.J., and Morison, I.M. (2015). Genome-wide DNA methylation map of human neutrophils reveals widespread inter-individual epigenetic variation. Sci. Rep., 5.","DOI":"10.1038\/srep17328"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"5664","DOI":"10.1182\/blood-2011-07-368746","article-title":"Epigenetic and molecular profiles of erythroid cells after hydroxyurea treatment in sickle cell anemia","volume":"118","author":"Walker","year":"2011","journal-title":"Blood"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S1470-2045(16)30558-7","article-title":"Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): A randomised, open-label, phase 3b study","volume":"18","author":"Passamonti","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s00277-017-2994-x","article-title":"Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study","volume":"96","author":"Vannucchi","year":"2017","journal-title":"Ann. Hematol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/PPO.0000000000000169","article-title":"Treatment of Myelofibrosis: A Moving Target","volume":"22","author":"Cerquozzi","year":"2016","journal-title":"Cancer J."},{"key":"ref_151","doi-asserted-by":"crossref","unstructured":"Kent, D.G., Li, J., Tanna, H., Fink, J., Kirschner, K., Pask, D.C., Silber, Y., Hamilton, T.L., Sneade, R., and Simons, B.D. (2013). Self-renewal of single mouse hematopoietic stem cells is reduced by JAK2V617F without compromising progenitor cell expansion. PLoS Biol., 11.","DOI":"10.1371\/journal.pbio.1001576"},{"key":"ref_152","doi-asserted-by":"crossref","unstructured":"Greenfield, G., McPherson, S., Smith, J., Mead, A., Harrison, C., Mills, K., and McMullin, M.F. (2020). Modification of the Histone Landscape with JAK Inhibition in Myeloproliferative Neoplasms. Cancers, 12.","DOI":"10.3390\/cancers12092669"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/bjh.14269","article-title":"Application of an NGS-based 28-gene panel in myeloproliferative neoplasms reveals distinct mutation patterns in essential thrombocythaemia, primary myelofibrosis and polycythaemia vera","volume":"175","author":"Delic","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1186\/s12967-018-1729-7","article-title":"The ruxolitinib effect: Understanding how molecular pathogenesis and epigenetic dysregulation impact therapeutic efficacy in myeloproliferative neoplasms","volume":"16","author":"Greenfield","year":"2018","journal-title":"J. Transl. Med."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"e317","DOI":"10.1016\/S2352-3026(17)30088-1","article-title":"Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): A single-arm, open-label, non-randomised, phase 2, multicentre study","volume":"4","author":"Harrison","year":"2017","journal-title":"Lancet Haematol."},{"key":"ref_156","doi-asserted-by":"crossref","unstructured":"Singer, J.W., Al-Fayoumi, S., Taylor, J., Velichko, S., and O\u2019Mahony, A. (2019). Comparative phenotypic profiling of the JAK2 inhibitors ruxolitinib, fedratinib, momelotinib, and pacritinib reveals distinct mechanistic signatures. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0222944"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"e335","DOI":"10.1038\/bcj.2015.63","article-title":"A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis","volume":"5","author":"Pardanani","year":"2015","journal-title":"Blood Cancer J."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"10777","DOI":"10.2147\/CMAR.S212559","article-title":"Beyond Ruxolitinib: Fedratinib and Other Emergent Treatment Options for Myelofibrosis","volume":"11","author":"Bewersdorf","year":"2019","journal-title":"Cancer Manag. Res."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"4509","DOI":"10.2147\/OTT.S267001","article-title":"Clinical Utility of Fedratinib in Myelofibrosis","volume":"14","author":"Waksal","year":"2021","journal-title":"Onco Targets Ther."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13045-021-01157-4","article-title":"Momelotinib: An emerging treatment for myelofibrosis patients with anemia","volume":"15","author":"Chifotides","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s13045-020-00995-y","article-title":"Novel therapeutics in myeloproliferative neoplasms","volume":"13","author":"Venugopal","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1182\/bloodadvances.2019000167","article-title":"Imetelstat inhibits growth of megakaryocyte colony-forming units from patients with essential thrombocythemia","volume":"3","author":"Baerlocher","year":"2019","journal-title":"Blood Adv."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1007\/s40265-024-02080-x","article-title":"Imetelstat: First Approval","volume":"84","author":"Keam","year":"2024","journal-title":"Drugs"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"e70076","DOI":"10.1111\/cts.70076","article-title":"Imetelstat, a novel, first-in-class telomerase inhibitor: Mechanism of action, clinical, and translational science","volume":"17","author":"Lennox","year":"2024","journal-title":"Clin. Transl. Sci."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s13148-011-0050-6","article-title":"Epigenetic abnormalities in myeloproliferative neoplasms: A target for novel therapeutic strategies","volume":"2","author":"Mascarenhas","year":"2011","journal-title":"Clin. Epigenet."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1007\/s10637-019-00794-4","article-title":"Cotargeting the JAK\/STAT signaling pathway and histone deacetylase by ruxolitinib and vorinostat elicits synergistic effects against myeloproliferative neoplasms","volume":"38","author":"Hao","year":"2020","journal-title":"Investig. New Drugs"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.exphem.2019.09.025","article-title":"Methylation age as a correlate for allele burden, disease status, and clinical response in myeloproliferative neoplasm patients treated with vorinostat","volume":"79","author":"McPherson","year":"2019","journal-title":"Exp. Hematol."},{"key":"ref_168","doi-asserted-by":"crossref","unstructured":"Horvath, S. (2013). DNA methylation age of human tissues and cell types. Genome Biol., 14, Erratum in: Genome Biol. 2015, 16, 96. https:\/\/doi.org\/10.1186\/s13059-015-0649-6.","DOI":"10.1186\/s13059-015-0649-6"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/bjh.12384","article-title":"Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia vera myelofibrosis","volume":"162","author":"DeAngelo","year":"2013","journal-title":"Br. J. Haematol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"4993","DOI":"10.1200\/JCO.22.01972","article-title":"MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Na\u00efve Myelofibrosis","volume":"41","author":"Mascarenhas","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.2217\/fon-2022-0484","article-title":"Phase III MANIFEST-2: Pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosis","volume":"18","author":"Harrison","year":"2022","journal-title":"Future Oncol."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"5483","DOI":"10.1038\/sj.onc.1205699","article-title":"5-Azacytidine and 5-aza-2\u2032-deoxycytidine as inhibitors of DNA methylation: Mechanistic studies and their implications for cancer therapy","volume":"21","author":"Christman","year":"2002","journal-title":"Oncogene"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"5735","DOI":"10.1182\/bloodadvances.2024013215","article-title":"A multicenter phase 2 clinical trial of low-dose subcutaneous decitabine in myelofibrosis","volume":"8","author":"Lin","year":"2024","journal-title":"Blood Adv."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.7314\/APJCP.2015.16.6.2219","article-title":"Methylated alteration of SHP1 complements mutation of JAK2 tyrosine kinase in patients with myeloproliferative neoplasm","volume":"16","author":"Yang","year":"2015","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1159\/000506146","article-title":"Clinical Benefit Derived from Decitabine Therapy for Advanced Phases of Myeloproliferative Neoplasms","volume":"144","author":"Zhou","year":"2021","journal-title":"Acta Haematol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1159\/000512929","article-title":"Accelerated Phase of Myeloproliferative Neoplasms","volume":"144","author":"Shahin","year":"2021","journal-title":"Acta Haematol."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/s41408-023-00878-8","article-title":"Blast phase myeloproliferative neoplasm: Contemporary review and 2024 treatment algorithm","volume":"13","author":"Tefferi","year":"2023","journal-title":"Blood Cancer J."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/j.1600-0609.2010.01433.x","article-title":"Epigenetic therapy in myelodysplastic syndromes","volume":"84","author":"Musolino","year":"2010","journal-title":"Eur. J. Haematol."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s40265-024-02052-1","article-title":"Givinostat: First Approval","volume":"84","author":"Lamb","year":"2024","journal-title":"Drugs"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/sj.leu.2405049","article-title":"The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F)","volume":"22","author":"Guerini","year":"2008","journal-title":"Leukemia"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1038\/s41375-020-0735-y","article-title":"Safety and efficacy of the maximum tolerated dose of givinostat in polycythemia vera: A two-part Phase Ib\/II study","volume":"34","author":"Rambaldi","year":"2020","journal-title":"Leukemia"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1365-2141.2010.08266.x","article-title":"A pilot study of the Histone-Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms","volume":"150","author":"Rambaldi","year":"2010","journal-title":"Br. J. Haematol."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/bjh.12332","article-title":"A phase II study of Givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy","volume":"61","author":"Finazzi","year":"2013","journal-title":"Br. J. Haematol."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1182\/blood-2013-11-536854","article-title":"The orally bioavailable MDM2 antagonist RG7112 and pegylated interferon \u03b1 2a target JAK2V617F-positive progenitor and stem cells","volume":"124","author":"Lu","year":"2014","journal-title":"Blood"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1182\/blood-2014-04-569525","article-title":"Lysine-specific demethylase 1 (LSD1) in hematopoietic and lymphoid neoplasms","volume":"124","author":"Niebel","year":"2014","journal-title":"Blood"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1097\/HS9.0000000000000054","article-title":"LSD1 Inhibition Prolongs Survival in Mouse Models of MPN by Selectively Targeting the Disease Clone","volume":"2","author":"Jutzi","year":"2018","journal-title":"Hemasphere"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"6533","DOI":"10.3390\/cimb46070390","article-title":"Translation of Epigenetics in Cell-Free DNA Liquid Biopsy Technology and Precision Oncology","volume":"46","author":"Tan","year":"2024","journal-title":"Curr. Issues Mol. Biol."},{"key":"ref_188","doi-asserted-by":"crossref","unstructured":"Allegra, A., Tonacci, A., Sciaccotta, R., Genovese, S., Musolino, C., Pioggia, G., and Gangemi, S. (2022). Machine Learning and Deep Learning Applications in Multiple Myeloma Diagnosis, Prognosis, and Treatment Selection. Cancers, 14.","DOI":"10.3390\/cancers14030606"},{"key":"ref_189","doi-asserted-by":"crossref","unstructured":"Allegra, A., Mirabile, G., Tonacci, A., Genovese, S., Pioggia, G., and Gangemi, S. (2023). Ma+chine Learning Approaches in Diagnosis, Prognosis and Treatment Selection of Cardiac Amyloidosis. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24065680"},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"E818","DOI":"10.1097\/HS9.0000000000000818","article-title":"Machine learning improves risk stratification in myelofibrosis: An analysis of the spanish registry of myelofibrosis","volume":"7","author":"Raya","year":"2023","journal-title":"Hemasphere"},{"key":"ref_191","first-page":"522","article-title":"Analysis of DNA Methylation Gene Mutations and Clinical Features in Patients with Myeloproliferative Neoplasm","volume":"30","author":"Wang","year":"2022","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"}],"container-title":["Current Issues in Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1467-3045\/47\/4\/227\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:02:28Z","timestamp":1760029348000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1467-3045\/47\/4\/227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,26]]},"references-count":191,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["cimb47040227"],"URL":"https:\/\/doi.org\/10.3390\/cimb47040227","relation":{},"ISSN":["1467-3045"],"issn-type":[{"value":"1467-3045","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,26]]}}}